These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 17353113)

  • 1. Leishmania spp.: proficiency of drug-resistant parasites.
    Natera S; Machuca C; Padrón-Nieves M; Romero A; Díaz E; Ponte-Sucre A
    Int J Antimicrob Agents; 2007 Jun; 29(6):637-42. PubMed ID: 17353113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.
    Goyeneche-Patino DA; Valderrama L; Walker J; Saravia NG
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4503-6. PubMed ID: 18824610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro assays for evaluation of drug activity against Leishmania spp.
    Fumarola L; Spinelli R; Brandonisio O
    Res Microbiol; 2004 May; 155(4):224-30. PubMed ID: 15142618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?
    Yardley V; Ortuno N; Llanos-Cuentas A; Chappuis F; Doncker SD; Ramirez L; Croft S; Arevalo J; Adaui V; Bermudez H; Decuypere S; Dujardin JC
    J Infect Dis; 2006 Oct; 194(8):1168-75. PubMed ID: 16991093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fitness of antimony-resistant Leishmania parasites: lessons from the field.
    Ait-Oudhia K; Gazanion E; Oury B; Vergnes B; Sereno D
    Trends Parasitol; 2011 Apr; 27(4):141-2. PubMed ID: 21216196
    [No Abstract]   [Full Text] [Related]  

  • 6. Cellular Markers for the Identification of Chemoresistant Isolates in Leishmania.
    Padrón-Nieves M; Ponte-Sucre A
    Methods Mol Biol; 2020; 2116():755-769. PubMed ID: 32221953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of antimony resistance in Leishmania.
    Ashutosh ; Sundar S; Goyal N
    J Med Microbiol; 2007 Feb; 56(Pt 2):143-53. PubMed ID: 17244793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania.
    Marquis N; Gourbal B; Rosen BP; Mukhopadhyay R; Ouellette M
    Mol Microbiol; 2005 Sep; 57(6):1690-9. PubMed ID: 16135234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity, toxicity and analysis of resistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral and intralesional administration in BALB/c mice infected with Leishmania amazonensis: a preliminary study.
    Monzote L; Montalvo AM; Scull R; Miranda M; Abreu J
    Biomed Pharmacother; 2007; 61(2-3):148-53. PubMed ID: 17254746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mechanism of drug resistance in kala azar field isolates.
    Singh N; Singh RT; Sundar S
    J Infect Dis; 2003 Aug; 188(4):600-7. PubMed ID: 12898450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parasitology. Drugs to combat tropical protozoan parasites.
    Gelb MH; Hol WG
    Science; 2002 Jul; 297(5580):343-4. PubMed ID: 12130767
    [No Abstract]   [Full Text] [Related]  

  • 12. Antimicrobial peptides for leishmaniasis.
    Cobb SL; Denny PW
    Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances and perspectives in Leishmania cell based drug-screening procedures.
    Sereno D; Cordeiro da Silva A; Mathieu-Daude F; Ouaissi A
    Parasitol Int; 2007 Mar; 56(1):3-7. PubMed ID: 17079188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
    Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
    Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.
    Yardley V; Croft SL; De Doncker S; Dujardin JC; Koirala S; Rijal S; Miranda C; Llanos-Cuentas A; Chappuis F
    Am J Trop Med Hyg; 2005 Aug; 73(2):272-5. PubMed ID: 16103588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin.
    Gourbal B; Sonuc N; Bhattacharjee H; Legare D; Sundar S; Ouellette M; Rosen BP; Mukhopadhyay R
    J Biol Chem; 2004 Jul; 279(30):31010-7. PubMed ID: 15138256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
    Pérez-Victoria FJ; Sánchez-Cañete MP; Seifert K; Croft SL; Sundar S; Castanys S; Gamarro F
    Drug Resist Updat; 2006; 9(1-2):26-39. PubMed ID: 16814199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
    Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
    J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation.
    Abdo MG; Elamin WM; Khalil EA; Mukhtar MM
    East Mediterr Health J; 2003 Jul; 9(4):837-43. PubMed ID: 15748080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An in vitro micromethod for drug sensitivity testing of Leishmania.
    Jackson JE; Tally JD; Tang DB
    Am J Trop Med Hyg; 1989 Sep; 41(3):318-30. PubMed ID: 2552851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.